Phase II study alternating mFOLFOX 6 and FOLFIRI (FIREFOX) plus bevacizumab (bev) regimen in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0801).

被引：0
|
作者：
Ogata, Yutaka
Akagi, Yoshito
Kakeji, Yoshihiro
Emi, Yasunori
Oki, Eiji
Saeki, Hiroshi
Touyama, Tetsuo
Samura, Hironori
Baba, Hideo
Natsugoe, Shoji
Shirouzu, Kazuo
Tokunaga, Shoji
Maehara, Yoshihiko
机构：
[1] Kurume Univ, Dept Surg, Kurume Med Ctr, Sch Med, Kurume, Fukuoka, Japan
[2] Kurume Univ, Dept Surg, Sch Med, Kurume, Fukuoka, Japan
[3] Kyushu Univ, Dept Surg & Sci, Fukuoka, Japan
[4] Nakagami Hosp, Okinawa, Japan
[5] Univ Ryukyus, Dept Surg 1, Nishihara, Okinawa, Japan
[6] Kumamoto Univ, Dept Surg Gastroenterol, Kumamoto, Japan
[7] Kagashima Univ, Dept Gastrointestinal Surg, Kagoshima, Japan
[8] Kyushu Univ Hosp, Med Informat Ctr, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.602
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
602
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
    Zhou, F.
    Wang, W.
    Xia, L.
    Dai, J.
    Wu, H.
    Yang, L.
    Gong, J.
    Chen, X.
    Xiong, Z.
    Liang, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S439 - S439
  • [22] THE EFFICACY AND SAFETY OF BEVACIZUMAB BEYOND FIRST PROGRESSION IN JAPANESE PATIENTS TREATED WITH FIRST-LINE MFOLFOX6 FOLLOWED BY SECOND-LINE FOLFIRI IN ADVANCED COLORECTAL CANCER: A MULTICENTER, SINGLE-ARM PHASE II TRIAL (CCOG-0801); FINAL REPORT
    Nakayama, G.
    Ishigure, K.
    Ishiyama, A.
    Uehara, K.
    Fujii, T.
    Hayashi, N.
    Ando, Y.
    Kodera, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 220 - 220
  • [23] Liver resectability following mFOLFOX6 with bevacizumab as the first-line treatment of unresectable liver limited metastases from colorectal cancer in Japanese patients (KSCC 0802).
    Samura, Hironori
    Beppu, Toru
    Emi, Yasunori
    Kakeji, Yoshihiro
    Saeki, Hiroshi
    Oki, Eiji
    Fujita, Fumihiko
    Inomata, Masahumi
    Sawai, Terumitsu
    Akagi, Yoshito
    Baba, Hideo
    Natsugoe, Shoji
    Ogata, Yutaka
    Tokunaga, Shoji
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [24] LIVER RESECTABILITY FOLLOWING MFOLFOX6 WITH BEVACIZUMAB AS THE FIRST-LINE TREATMENT OF UNRESECTABLE LIVER LIMITED METASTASES FROM COLORECTAL CANCER IN JAPANESE PATIENTS (KSCC 0802)
    Akagi, Y.
    Beppu, T.
    Emi, Y.
    Kakechi, Y.
    Saeki, H.
    Oki, E.
    Fujita, F.
    Inomata, M.
    Sawai, T.
    Samura, H.
    Baba, H.
    Natsugoe, S.
    Ogata, Y.
    Tokunaga, S.
    Maehara, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 82 - 83
  • [25] The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801)
    Nakayama, Goro
    Uehara, Keisuke
    Ishigure, Kiyoshi
    Yokoyama, Hiroyuki
    Ishiyama, Akiharu
    Eguchi, Takehiko
    Tsuboi, Kenji
    Ohashi, Norifumi
    Fujii, Tsutomu
    Sugimoto, Hiroyuki
    Koike, Masahiko
    Fujiwara, Michitaka
    Ando, Yuich
    Kodera, Yasuhiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 575 - 581
  • [26] The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801)
    Goro Nakayama
    Keisuke Uehara
    Kiyoshi Ishigure
    Hiroyuki Yokoyama
    Akiharu Ishiyama
    Takehiko Eguchi
    Kenji Tsuboi
    Norifumi Ohashi
    Tsutomu Fujii
    Hiroyuki Sugimoto
    Masahiko Koike
    Michitaka Fujiwara
    Yuich Ando
    Yasuhiro Kodera
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 575 - 581
  • [27] A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
    Van Cutsem, E.
    Prenen, H.
    D'Haens, G.
    Bennouna, J.
    Carrato, A.
    Ducreux, M.
    Bouche, O.
    Sobrero, A.
    Latini, L.
    Staines, H.
    Oum'Hamed, Z.
    Dressler, H.
    Studeny, M.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2015, 26 (10) : 2085 - 2091
  • [28] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ahmet, Bilici
    Uygun, Kazim
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
  • [29] A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101)
    Ando, Koji
    Emi, Yasunori
    Suenaga, Toyokuni
    Hamanoue, Masahiro
    Maekawa, Soichiro
    Sakamoto, Yasuo
    Kai, Seiichiro
    Satake, Hironaga
    Shimose, Takayuki
    Shimokawa, Mototsugu
    Saeki, Hiroshi
    Oki, Eiji
    Sakai, Kenji
    Akagi, Yoshito
    Baba, Hideo
    Maehara, Yoshihiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (05) : 913 - 920
  • [30] A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101)
    Koji Ando
    Yasunori Emi
    Toyokuni Suenaga
    Masahiro Hamanoue
    Soichiro Maekawa
    Yasuo Sakamoto
    Seiichiro Kai
    Hironaga Satake
    Takayuki Shimose
    Mototsugu Shimokawa
    Hiroshi Saeki
    Eiji Oki
    Kenji Sakai
    Yoshito Akagi
    Hideo Baba
    Yoshihiko Maehara
    International Journal of Clinical Oncology, 2017, 22 : 913 - 920
12345